novo nordisk - Search News

News

Wegovy, Novo Nordisk

Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly ,

Seeking Alpha on MSN · 20h

Novo Nordisk plans cost cuts amid slower Wegovy growth outlook

Novo Nordisk (NVO) said Wednesday it will cut costs as it faces increasing competition from Eli Lilly (LLY) and generic versions of its obesity drug Wegovy, with slower growth expected for its treatments in the second half of the year.

The Wall Street Journal on MSN · 21h

Novo Nordisk’s Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded versions of the drug.

17h

Novo Nordisk, TSMC, Glencore: Stocks Around the World in Focus

The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...

14h

Ozempic Maker Novo Nordisk Terminates Multiple Pipeline Programs, Faces Investor Lawsuit Over GLP-1 Market Misrepresentation

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

1hon MSN

Novo Nordisk (NVO) Gets Downgraded to Neutral from Buy at UBS

Novo Nordisk A/S (NYSE:NVO) is one of the top NYSE stocks with the highest upside potential. On August 5, UBS downgraded Novo ...

5hon MSN

Why Novo Nordisk Stock Slipped Today

Novo Nordisk ( NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...

Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli Lilly

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

2don MSN

Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop

Novo Nordisk's U.S.-listed shares shed a third of their value last week after the company cut its full-year outlook and named ...

11h

Novo Nordisk to advance ATTR amyloidosis mAb to Phase III

Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results